What's Happening?
A novel approach to treating sepsis by filtering a specific protein from the blood has shown promising results in animal models. The technique involves removing the protein galectin-3, which is believed to drive the life-threatening reaction of sepsis.
Developed by Isaac Eliaz and his team, the method uses a device to extract blood, separate plasma, filter out galectin-3, and return the treated blood to the patient. Initial tests in rats and miniature pigs demonstrated improved survival rates, suggesting potential for human trials.
Why It's Important?
Sepsis is a critical condition with high mortality rates, affecting millions worldwide. Current treatments focus on managing infections and organ damage, but this new method targets a specific protein involved in the sepsis process. If successful in human trials, this approach could revolutionize sepsis treatment, reducing mortality and improving patient outcomes. The technique's success could also pave the way for similar treatments targeting other conditions linked to galectin-3.
What's Next?
Eliaz Therapeutics is seeking funding for a randomized clinical trial in humans, planned for 2027. Further research is needed to understand the mechanistic role of galectin-3 in sepsis and to validate the technique's efficacy across different species. If successful, this could lead to widespread adoption of the treatment in clinical settings, offering a new lifeline for sepsis patients.
